Announcing a New Indication for a PERJETA
Genentech is excited to share the news of the FDA approval of PERJETA in combination with trastuzumab and chemotherapy as:
· Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer
· Adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence
The FDA approval letter for PERJETA can be found at
https://www.genentech-access.com/PERJETA
Genentech Access Solutions offers a range of access and reimbursement support to help patients begin treatment as soon as possible. We can help your patients by providing:
· Full benefits investigations
· Prior authorization resources
· Sample billing and coding information
· Resources for appeals
· Patient assistance options
For more information about PERJETA Access Solutions, please contact me directly, visit https://www.genentech-access.com/hcp/brands/perjeta.html or call 1-888-249-4918, Monday
through Friday, 6 AM–5 PM PT
